Xavier Mariette

Nov 19, 2024 | acrjournals.onlinelibrary.wiley.com | Thomas E. Dorner |Simon J. Bowman |Robert Fox |Xavier Mariette |Athena Papas |Filipe Barcelos | +7 more

Sep 27, 2024 | biorxiv.org | Loic Meudec |Xavier Mariette |Gaetane Nocturne |Ilya Gurevic

AbstractObjective: Our objective was to define the effect of JAK1/2 inhibitor (JAKinib) withdrawal on JAK/STAT biochemical response in the context of systemic rheumatic diseases. Methods: We tested Type I (bind kinase active conformation) and Type II (bind kinase inactive conformation) JAKinibs in vitro using mesenchymal stromal cells and endothelial cells. We translated our findings in vivo studying NK cells from rheumatoid arthritis (RA) patients treated with Type I JAKinibs or methotrexate.

Jun 12, 2024 | ard.bmj.com | Xavier Mariette |Hôpital Bicêtre

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

May 6, 2024 | thelancet.com | Michele Bombardieri |Jacques-Olivier Pers |Xavier Mariette |Saviana Gandolfo

1. Seror R Nocturne G Mariette X Current and future therapies for primary Sjögren syndrome. Nat Rev Rheumatol. 2021; 17: 475-4862. Ramos-Casals M Brito-Zerón P Bombardieri S et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020; 79: 3-183. Emerging drugs for primary Sjögren's syndrome. Expert Opin Emerg Drugs. 2019; 24: 121-1324. Primary Sjögren's syndrome. N Engl J Med. 2018; 378: 931-9395. Yates LR Seoane J Tourneau CL et al.

Jan 3, 2024 | ard.bmj.com | Xavier Mariette |Hôpital Bicêtre

Covid-19FibromyalgiaEpidemiologyI thank Robert Landewe1 for his interest and consent regarding my viewpoint on the resemblance between ‘long COVID’ and fibromyalgia.2 I do agree with him that naming a problem is not sufficient. However, the question of naming is not secondary.